NSCLC restriction and item codes
Do not share these attachments externally. See Freedom of Information - Information Publication Scheme.
PBS NSCLC restriction and item codes
Contact details
PBS Complex Drugs Programs
Forms
Non-small cell lung cancer - initial authority application (PB156)
Services Australia website
Non-small cell lung cancer
External websites
PBS schedule for non-small cell lung cancer
FAQs from Service Officers
Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.
Item | Description |
1 | Can patients switch between crizotinib and entrectinib? There is no change restriction. To switch between crizotinib and entrectinib, an initial application must be submitted for the required medication. The alternate agent can only be requested due to intolerance, not failure. |
2 | Can patients switch from crizotinib/entrectinib to repotrectinib? There is no change restriction. To access repotrectinib, an initial application must be submitted. Repotrectinib can be requested even if the patient has failed crizotinib and/or entrectinib. |
3 | Does a patient have to requalify if there is a break in treatment? No. Poviding the patient did not develop disease progression whilst receiving PBS-subsidised treatment, continuing treatment can be requested irrespective of any breaks in therapy. |
Expand all